The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth.

The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth. Abstract Text:

M S Kim,X Chang,J K Nagpal,K Yamashita,J H Baek,S Dasgupta,G Wu,M Osada,J-H Woo,W H Westra,B Trink,E A Ratovitski,C Moon,D Sidransky,

N-methyl-D-aspartate receptors (NMDARs) are the predominant excitatory neurotransmitter receptors in the mammalian brain. We found that among the three NMDARs examined (NMDAR1, NMDAR2A, NMDAR2B), only NMDAR2A was silenced in colorectal carcinoma (CRC) cell lines at basal line and reactivated by the demethylating agent, 5-aza-2'-deoxycytidine. NMDAR2A was expressed in normal colon epithelium, while expression was hardly detectable in colon cancer tissues. Promoter methylation of NMDAR2A was confirmed by bisulfite sequencing and combined bisulfite restriction analysis in the CRC cell lines and primary tumors. Quantitative methylation-specific PCR demonstrated NMDAR2A promoter hypermethylation in 82 of 100 primary human CRC, 15 of 100 normal corresponding epithelial tissues and 1 of 11 (9%) normal colon mucosa samples obtained from patients without cancer. Moreover, forced expression of full-length NMDAR2A in CRC cell lines induced apoptosis and almost abolished the ability of the cells to form colonies in culture, while NMDAR2A knockdown increased cell growth. Thus, NMDAR2A is commonly hypermethylated in primary human CRC and possesses tumor-suppressive activity.

The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth. Publishing Authors By Initials

MS Kim,X Chang,JK Nagpal,K Yamashita,JH Baek,S Dasgupta,G Wu,M Osada,JH Woo,WH Westra,B Trink,EA Ratovitski,C Moon,D Sidransky,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Oncogene

VOLUME: 27

Page Numbers: 2045-54

Journal Abbreviation: Oncogene

ISSN: 1476-5594

DAY: 8

MONTH: 10

YEAR: 2007

The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8711562

The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth.

AFFILIATION: Department of Otolaryngology, Head and Neck Cancer Research Division, Johns Hopkins University, Baltimore, MD, USA.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Oncogene

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth Related Publications

• A Promoter Methylation Pattern in the N-Methyl-D-Aspartate Receptor 2B Gene Predicts Poor Prognosis in Esophageal Squamous Cell Carcinoma.
• A p53-type response element in the GDF15 promoter confers high specificity for p53 activation.
• A transplantable rat hepatocellular carcinoma induced by ethionine.
• Aberrant promoter methylation and tumor suppressive activity of the DFNA5 gene in colorectal carcinoma.
• Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer.
• DCC promoter hypermethylation in esophageal squamous cell carcinoma.
• DeltaNp63alpha overexpression induces downregulation of Sirt1 and an accelerated aging phenotype in the mouse.
• Gaucher disease and the synucleinopathies.
• Gaucher disease associated with parkinsonism: four further case reports.
• Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA).
• Genome-wide promoter analysis uncovers portions of the cancer methylome.
• Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease.
• HOP/OB1/NECC1 Promoter DNA Is Frequently Hypermethylated and Involved in Tumorigenic Ability in Esophageal Squamous Cell Carcinoma.
• Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer.
• Isolation of two lines of transplantable, ethionine-induced rat hepatomas of high and low catalase activity from a primary tumor.
• Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancer.
• Mitochondrial cytochrome B gene mutation promotes tumor growth in bladder cancer.
• Quantitative hypermethylation of NMDAR2B in human gastric cancer.
• Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions.
• Slow development impedes the uptake of diagnostics.
• Targeting human 8-oxoguanine DNA glycosylase to mitochondria protects cells from 2-methoxyestradiol-induced-mitochondria-dependent apoptosis.
• Targeting of mutant hogg1 in mammalian mitochondria and nucleus: effect on cellular survival upon oxidative stress.
• The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth.
• The need for appropriate genotyping strategies for glucocerebrosidase mutations in cohorts with Parkinson disease.
• The role of PGP9.5 as a tumor suppressor gene in human cancer.
• Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer.
• Treating patients with Gaucher disease and parkinsonism: Misrepresentation in a title.
• U-box-type ubiquitin E4 ligase, UFD2a attenuates cisplatin mediated degradation of DeltaNp63alpha.
• Uniparental disomy of chromosome 1 causing concurrent charcot-marie-tooth and Gaucher disease type 3.
• ssDNA-Binding Protein 2 Is Frequently Hypermethylated and Suppresses Cell Growth in Human Prostate Cancer.